INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 23, 2021 Category: Pharmaceuticals Source Type: clinical trials
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial
In this study, block randomization will be used, in blocks of 6.Blinding (masking)This is an open label trial. Trial participants, investigators, care givers, outcome assessors, and date analysts are not blinded to group assignment.Numbers to be randomised210 patients are expected to be enrolled and allocated according to the ratio of 2 (Favipiravir group, n=140): 1(regular treatment group, n=70).Trial StatusProtocol version number 3.0, 10th April 2020First Patient, first visit 17th March 2020; recruitment end date anticipated June 1, 2020.Trial registrationClinicalTrials.gov,NCT04333589, April 3, 2020. Registered April 3,...
Source: Trials - June 4, 2020 Category: Research Source Type: clinical trials
Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever
Condition: Lassa Fever Intervention: Sponsor: University of Oxford Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2020 Category: Research Source Type: clinical trials
